Marquest Medical
This article was originally published in The Gray Sheet
Executive Summary
Will shut down its Nogales, Mexico operations and integrate them into its central manufacturing facility in Englewood, Colorado. FDA cited the Mexican plant for GMP violations last July ("The Gray Sheet" Nov. 16, 1992, p. 5). The consolidation is part of a broad restructuring effort, which also included the sale of Marquest's Parker, Colorado facility in January and ongoing financing negotiations with Scherer Healthcare ("The Gray Sheet" Jan. 18, p. 15). The restructuring was undertaken to finance costs associated with an October 1991 consent decree that required the firm to cease U.S. operations until it could demonstrate compliance with GMPs. The revalidation and product reintroduction process "is now essentially complete," Marquest says.